Patients with pulmonary arterial hypertension experienced a significant improvement in World Health Organization Functional Class when transitioned from a phosphodiesterase type 5 inhibitor to riociguat.
Positive results with respect to the presence of latent tuberculosis infection in patients with renal failure were more consistent with the use of QuantiFERON-TB Gold Plus testing compared with the use of QuantiFERON-TB Gold In-Tube testing.
Based on the 2016 International Working Group (IWG) diagnostic criteria for idiopathic pulmonary fibrosis (IPF), outcomes are relatively similar between patients with IPF with pneumonia and patients with an acute IPF exacerbation.
Patients with COPD who have the most severe airflow obstructions according to the GOLD strategy document had more exacerbations than those with less severe obstructions, and were more likely to be treated with both systemic corticosteroids and antibiotics.
Individuals with moderate to very severe COPD and cardiovascular risk factors did not have an increased risk for all-cause mortality or major adverse cardiovascular event occurrence with the use of aclidinium.